Pharma major Dr Reddy’s Laboratories has received approval from the U.S. Food and Drug Administration (USFDA) to launch Doxorubicin Hydrochloride Liposome Injection, a therapeutic equivalent generic version of Doxil (doxorubicin hydrochloride liposome injection), for intravenous use, in the United States market.
USFDA approval is an outcome of extensive collaboration with the company's partner, Natco Pharma, on R&D and manufacturing capabilities. According to IMS Health, the Doxil brand and generic had U.S. sales of approximately $196 million MAT for the most recent twelve months ending in March 2017.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
